• 1.

    Ott JJ, Stevens GA, Groeger J, Wiersma ST, 2012. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 30: 22122219.

    • Search Google Scholar
    • Export Citation
  • 2.

    Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS, 2005. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 34: 13291339.

    • Search Google Scholar
    • Export Citation
  • 3.

    Clements CJ, Baoping Y, Crouch A, Hipgrave D, Mansoor O, Nelson CB, Treleaven S, van Konkelenberg R, Wiersma S, 2006. Progress in the control of hepatitis B infection in the Western Pacific Region. Vaccine 24: 19751982.

    • Search Google Scholar
    • Export Citation
  • 4.

    Hennessey K, Mendoza-Aldana J, Bayutas B, Lorenzo-Mariano KM, Diorditsa S, 2013. Hepatitis B control in the World Health Organization's Western Pacific Region: targets, strategies, status. Vaccine 31 (Suppl 9): J85J92.

    • Search Google Scholar
    • Export Citation
  • 5.

    Regional Committee of the Western Pacific, 2013. Hepatitis B Control through Vaccination: Setting the Target. WPR/RC64.R5. Manila, Philippines: WHO Regional Office for the Western Pacific.

    • Search Google Scholar
    • Export Citation
  • 6.

    World Health Organization, 2007. Western Pacific Regional Plan for Hepatitis B Control through Immunization. Manila, Philippines: WHO Regional Office for the Western Pacific.

    • Search Google Scholar
    • Export Citation
  • 7.

    Boutin JP, Sainte Marie FF, Cartel JL, Cardines R, Girard M, Roux J, 1990. Prevalence of hepatitis B virus infection in the Austral archipelago, French Polynesia: identification of transmission patterns for the formulation of immunization strategies. Trans R Soc Trop Med Hyg 84: 283287.

    • Search Google Scholar
    • Export Citation
  • 8.

    Brindle RJ, Eglin RP, Parsons AJ, Hill AV, Selkon JB, 1988. HTLV-1, HIV-1, hepatitis B and hepatitis delta in the Pacific and south-east Asia: a serological survey. Epidemiol Infect 100: 153156.

    • Search Google Scholar
    • Export Citation
  • 9.

    Renou L, Ségalin J-M, 2013. Evaluation de la Couverture Vaccinale des élèves scolarisés en Polynésie française, année scolaire 2011–2012. Tahiti, Polynésie Française: Direction de la Santé.

    • Search Google Scholar
    • Export Citation
  • 10.

    Lien TX, Tien NT, Chanpong GF, Cuc CT, Yen VT, Soderquist R, Laras K, Corwin A, 2000. Evaluation of rapid diagnostic tests for the detection of human immunodeficiency virus types 1 and 2, hepatitis B surface antigen, and syphilis in Ho Chi Minh City, Vietnam. Am J Trop Med Hyg 62: 301309.

    • Search Google Scholar
    • Export Citation
  • 11.

    Alere, 2011. Alere Determine HBsAg Package Insert. Available at: http://www.alere.com/en/home/product-details/determine-hbsag.html. Chiba, Japan: Alere.

    • Search Google Scholar
    • Export Citation
  • 12.

    World Health Organization, 2001. Hepatitis B Surface Antigen Assays: Operational Characteristics (Phase 1). Report 1. Geneva, Switzerland: World Health Organization.

    • Search Google Scholar
    • Export Citation
  • 13.

    Rubin D, Schenker N, 1987. Logit-based interval estimation for binomial data using the Jeffrey's prior. Sociol Methodol 17: 131144.

  • 14.

    World Health Organization, 2013. Global Vaccine Action Plan, 2011–2020. Geneva, Switzerland: World Health Organization.

  • 15.

    WHO Regional Office of the Western Pacific, 2011. Western Pacific Country Health Information Profiles: 2011 Revision. Geneva, Switzerland: World Health Organization.

    • Search Google Scholar
    • Export Citation
  • 16.

    Wallace AS, Sobel H, Ryman TK, Mantaring JB 3rd, Silvestre M, Thorley M, Ducusin J, Nyunt US, 2012. Timing of hepatitis B vaccination and impact of non-simultaneous vaccination with DTP vaccine following introduction of a hepatitis B birth dose in the Philippines. J Public Health Policy 33: 368381.

    • Search Google Scholar
    • Export Citation
  • 17.

    Clark A, Sanderson C, 2009. Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey data. Lancet 373: 15431549.

    • Search Google Scholar
    • Export Citation
  • 18.

    Hull BP, McIntyre PB, 2006. Timeliness of childhood immunisation in Australia. Vaccine 24: 44034408.

  • 19.

    Zhou Y, Wang H, Zheng J, Zhu X, Xia W, Hipgrave DB, 2009. Coverage of and influences on timely administration of hepatitis B vaccine birth dose in remote rural areas of the People's Republic of China. Am J Trop Med Hyg 81: 869874.

    • Search Google Scholar
    • Export Citation
  • 20.

    Bielicki JA, Achermann R, Berger C, 2012. Timing of measles immunization and effective population vaccine coverage. Pediatrics 130: e600e606.

    • Search Google Scholar
    • Export Citation
  • 21.

    Luman ET, Barker LE, Shaw KM, McCauley MM, Buehler JW, Pickering LK, 2005. Timeliness of childhood vaccinations in the United States: days undervaccinated and number of vaccines delayed. JAMA 293: 12041211.

    • Search Google Scholar
    • Export Citation
  • 22.

    Dominguez SR, Parrott JS, Lauderdale DS, Daum RS, 2004. On-time immunization rates among children who enter Chicago public schools. Pediatrics 114: e741e747.

    • Search Google Scholar
    • Export Citation
  • 23.

    Heininger U, Zuberbuhler M, 2006. Immunization rates and timely administration in pre-school and school-aged children. Eur J Pediatr 165: 124129.

    • Search Google Scholar
    • Export Citation
  • 24.

    Hill HA, Elam-Evans LD, Yankey D, Singleton JA, Kolasa M, 2015. National, state, and selected local area vaccination coverage among children aged 19–35 months—United States, 2014. MMWR 64: 889896.

    • Search Google Scholar
    • Export Citation
  • 25.

    World Health Organization, 2010. Hepatitis B vaccines: WHO position paper—recommendations. Vaccine 28: 589590.

  • 26.

    Ruff TA, Gertig DM, Otto BF, Gust ID, Sutanto A, Soewarso TI, Kandun N, Marschner IC, Maynard JE, 1995. Lombok Hepatitis B Model Immunization Project: toward universal infant hepatitis B immunization in Indonesia. J Infect Dis 171: 290296.

    • Search Google Scholar
    • Export Citation
  • 27.

    Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, Moyer LA, Bell BP, Alter MJ; Advisory Committee on Immunization Practices, 2005. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 54: 131.

    • Search Google Scholar
    • Export Citation
 
 
 

 

 
 
 

 

 

 

 

 

 

Hepatitis B Vaccination Coverage and Prevalence of Hepatitis B Surface Antigen Among Children in French Polynesia, 2014

View More View Less
  • Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia; Bureau des Programmes de Pathologies Infectieuses, Direction de la Santé, Papeete, French Polynesia

French Polynesia is considered to be moderately endemic for chronic hepatitis B virus infection, with an estimated 3% of the population having hepatitis B surface antigen (HBsAg). From 1990 to 1992, a 3-dose hepatitis B vaccination series was introduced into the routine infant immunization schedule in French Polynesia, including a birth dose (BD). In 2014, a nationally representative 2-stage cluster survey was undertaken to evaluate the impact of the vaccination program on HBsAg prevalence among school children (∼6 years of age) in Cours Préparatoire (CP). Documented vaccination data were reviewed for all eligible children; children with consent were tested for HBsAg with a rapid point-of-care test. In total, 1,660 students were identified; 1,567 (94%) had vaccination data for review and 1,196 (72%) participated in the serosurvey. Three-dose vaccination coverage was 98%, while timely BD coverage, defined as a dose administered within 24 hours of life, was 89%. Receipt of the second and third doses was often delayed, with 75% and 55% receiving a second and third dose within 1 month of the recommended age, respectively. No children tested positive for HBsAg. French Polynesia's vaccination program has achieved high coverage and an HBsAg seroprevalence of 0% (0–0.5%) among CP school children, but timeliness of vaccination could be improved.

Author Notes

* Address correspondence to Minal K. Patel, Global Immunization Division, Centers for Disease Control and Prevention, 1600 Clifton Road, MS E98, Atlanta, GA 30333. E-mail: hgo9@cdc.gov

Financial support: Funding for this survey was provided by the WHO.

Authors' addresses: Minal K. Patel and Kathleen Wannemuehler, Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, E-mails: hgo9@cdc.gov and kpw9@cdc.gov. Evelyne Le Calvez and Jean-Marc Ségalin, Bureau des Programmes de Pathologies Infectieuses, Direction de la Santé, Papeete, French Polynesia, E-mails: evelyne.lecalvez@sante.gov.pf and jean-marc.segalin@sante.gov.pf.

Save